COH 29

Drug Profile

COH 29

Alternative Names: COH-29

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator City of Hope National Medical Center; Novonco Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Leukaemia

Most Recent Events

  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Recurrent) in USA (PO) (NCT02112565)
  • 20 Jul 2015 Novonco plans a phase I trial for Ovarian cancer in USA
  • 20 Jul 2015 COH 29 licensed to Novonco worldwide for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top